Integer (NYSE:ITGR) Q4 2025 Earnings call February 19, 2026 09:00 AM ET Speaker7Good morning, and thank you for standing by. Welcome to Energous, excuse me, Integer Holdings Corporation's fourth quarter 2025 earnings call. My name is Audra, and I will be your conference operator today. At this time, all participants are in a listen-only mode. After the prepared remarks, there will be a question-and-answer session. Please note this call is being recorded. I would now like to turn the conference over to Krist ...

Key Takeaways BIO posted Q4 adjusted EPS of $2.51, missing estimates as shares sank 12.3%. BIO revenues rose 3.8% to $693.2M, led by Clinical Diagnostics growth of 8.4%. BIO guided 2026 currency-neutral revenue growth of 0.5-1.5% with 12-12.5% margin outlook.Bio-Rad Laboratories, Inc. (BIO) posted fourth-quarter 2025 adjusted earnings per share (EPS) of $2.51, which missed the Zacks Consensus Estimate by 2.3%. The bottom line decreased 13.4% from the prior-year quarter’s level.The quarter’s adjustments prim ...

Key Takeaways PODD reported Q4 EPS of $1.55, up 34.8%, as revenues rose 31.2% and beat estimates.Insulet's Omnipod sales climbed 33.5%, with international revenues surging more than 50%.PODD expanded gross and operating margins and guided 20%-22% CER revenue growth for 2026.Insulet Corporation (PODD) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.55, up 34.8% from the year-ago period’s figure. The bottom line surpassed the Zacks Consensus Estimate by 4.87%.GAAP EPS came in at $1.44, up ...

Integer Holdings Corporation (ITGR) Fourth Quarter 2025 Earnings Conference Call February 19, 2026 Presenters and Agenda Today's agenda: Kristen Stewart, CFA Director, Investor Relations CONFIDENTIAL | February 19, 2026 | 2 ITGR: 4Q25 Earnings Conference Call Payman Khales President, Chief Executive Officer Diron Smith Executive Vice President, Chief Financial Officer • Opening Remarks • Strategy Update • Financial Results • Financial Outlook • Wrap-up • Q&A Presentation of Financial Information & Forward-L ...

According to an SEC filing dated Feb. 18, Naya Capital Management UK Ltd disclosed a new position in Masimo (NASDAQ:MASI), acquiring nearly 1.6 million shares. Initiated a new position valued at about $203 million Position equals 15.3% of the fund’s 13F assets under management Masimo enters Naya Capital’s portfolio as one of only five reportable holdings What else to know Top positions after the filing: HUM: $318.4 million (24.0% of AUM) UNH: $301.3 million (22.7% of AUM) WWD: $297.1 mill ...

Performance in the Diversified segment improved primarily due to better net pricing realized during the fourth quarter.The acquisition of Shibo in China and DURECT's larsucosterol platform represent a strategic shift toward proactive business development to enhance long-term growth.Management attributed the 10% full-year adjusted EBITDA growth to portfolio optimization and increased operating leverage without the benefit of major acquisitions.International segment growth was supported by leading market posi ...

HINGHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that Harel Gadot, CEO, President and Chairman, will be a featured panelist at The Surgical Disruptive Technology Summit, which is part of SAGES NBT Innovation Weekend, taking place February 19-21 in Houston, TX. SAGES’s mission is to innovate, educate and collaborate to improve patient care, and the SAGES NBT Innovation Weekend se ...

THE WOODLANDS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Clarke Wilkirson, PhD, Clinical Development Engineer II, will present new long-term clinical data at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, happening March 5-7, 2026, in Phoenix, Arizona. The presentation, titled “Pain Mitigation in Pancreatic Adenocarcinoma: A ...

Core Viewpoint - Catheter Precision, Inc. has announced a definitive agreement to divest its atherectomy catheter technologies, enhancing capital efficiency and focusing on its high-growth electrophysiology platform [1][2]. Strategic Rationale - The transaction is expected to accelerate execution across the electrophysiology product portfolio while maintaining exposure to the future commercial success of the divested technologies [4]. Transaction Highlights - The company will receive an upfront cash payment of $15 million upon closing [7]. - It will retain a 5% equity stake in the acquiring company, with anti-dilution protection for up to $5 million of additional equity capital invested [7]. - A ten-year royalty payments agreement will be established, starting with a 1.5% baseline that increases to 3% on quarterly net sales exceeding $5 million [7]. - The transaction is designed to create potential long-term equity upside participation and recurring revenue through performance-based royalties [7]. Company Overview - Catheter Precision is a U.S.-based medical device company focused on advancing the treatment of cardiac arrhythmias through innovative electrophysiology technologies developed in collaboration with leading physicians [5].

Core Viewpoint - Edwards Lifesciences Corporation announced that its Chief Financial Officer, Scott Ullem, will present at two upcoming healthcare conferences in March 2026 [1] Conference Details - The first presentation is scheduled for Tuesday, March 10, 2026, at 10:00 a.m. ET at the Barclays 28th Annual Global Healthcare Conference [1] - The second presentation will take place on Wednesday, March 11, 2026, at 10:00 a.m. ET at the Leerink Global Healthcare Conference [1] - A live webcast of each presentation will be available on the Edwards investor relations website [1]